Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1508-1520

  Amirouchene Angelozzi, Nabil ^a   Nemati, Fariba ^a   Gentien, David ^a   Nicolas, André ^a   Dumont, Amaury ^a   Carita, Guillaume ^a   Camonis, Jacques ^a   Desjardins, Laurence ^a   Cassoux, Nathalie ^a   Piperno Neumann, Sophie ^a   Mariani, Pascale ^a   Sastre, Xavier ^a   Decaudin, Didier ^a   Roman Roman, Sergio ^a  

^a INSTITUT CURIE   (France)

Author keywords

BAP1; Cell lines; Everolimus; MTOR; Patients derived tumor xenografts; Uveal melanoma

Indexed keywords

BRCA1 ASSOCIATED PROTEIN 1; BRCA1 PROTEIN; EVEROLIMUS; LAGE1 ANTIGEN; LAGE2 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MELANOMA ANTIGEN 6; MELANOMA ANTIGEN C2; MONOPHENOL MONOOXYGENASE; NA17 ANTIGEN; PERIFOSINE; PROTEIN KINASE B; TRAMETINIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

92.1 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GNA11 GENE; GNAQ GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEL202 CELL LINE; MELANOMA CELL LINE; MM28 CELL LINE; MM33 CELL LINE; MM66 CELL LINE; MOUSE; MOUSE MODEL; MP34 CELL LINE; MP38 CELL LINE; MP41 CELL LINE; MP46 CELL LINE; MP55 CELL LINE; MP65 CELL LINE; NONHUMAN; OMM1 CELL LINE; OMM2.5 CELL LINE; ONCOGENE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UVEA MELANOMA;

EID: 84911976107     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.004     Document Type: Article

References (49)

1. Abdel-Rahman M.H., Yang Y., Zhou X.-P., Craig E.L., Davidorf F.H., Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. JCO 2006, 24:288-295.
2. Babchia N., Calipel A., Mouriaux F., Faussat A.-M., Mascarelli F. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Invest. Ophthalmol. Vis. Sci. 2010, 51:421-429.
3. Calipel A., Lefevre G., Pouponnot C., Mouriaux F., Eychène A., Mascarelli F. Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J.Biol. Chem. 2003, 278:42409-42418.
4. Carvajal R.D., Sosman J.A., Quevedo F., Milhem M.M., Joshua A.M., Kudchadkar R.R., Linette G.P., Gajewski T., Lutzky J., Lawson D.H., Lao C.D., Flynn P.J., Albertini M.R., Sato T., Paucar D., Panageas K.S., Dickson M.A., Wolchok J.D., Chapman P.B., Schwartz D.K. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J.Clin. Oncol. 2013, 31. (ASCO annual Meeting Abstracts).
5. Chen P.W., Murray T.G., Uno T., Salgaller M.L., Reddy R., Ksander B.R. Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin. Exp. Metastasis 1997, 15:509-518.
6. Chou T.-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
7. Chou T.-C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
8. Cohen Y., Goldenberg-Cohen N., Parrella P., Chowers I., Merbs S.L., Pe'er J., Sidransky D. Lack of BRAF mutation in primary uveal melanoma. IOVS 2003, 44:2876-2878.
9. Couturier J., Saule S. Genetic determinants of uveal melanoma. Dev. Ophthalmol. 2012, 49:150-165.
10. Cruz F., Rubin B.P., Wilson D., Town A., Schroeder A., Haley A., Bainbridge T., Heinrich M.C., Corless C.L. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003, 63:5761-5766.
11. Dangles-Marie V., Pocard M., Richon S., Weiswald L.-B., Assayag F., Saulnier P., Judde J.-G., Janneau J.-L., Auger N., Validire P., Dutrillaux B., Praz F., Bellet D., Poupon M.-F. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007, 67:398-407.
12. De Waard-Siebinga I., Blom D.J., Griffioen M., Schrier P.I., Hoogendoorn E., Beverstock G., Danen E.H., Jager M.J. Establishment and characterization of an uveal-melanoma cell line. Int. J. Cancer 1995, 62:155-161.
13. Dunavoelgyi R., Dieckmann K., Gleiss A., Sacu S., Kircher K., Georgopoulos M., Georg D., Zehetmayer M., Poetter R. Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81:199-205.
14. Edmunds S.C., Cree I.A., Dí Nícolantonío F., Hungerford J.L., Hurren J.S., Kelsell D.P. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Br. J. Cancer 2003, 88:1403-1405.
15. El-Hashemite N., Zhang H., Henske E.P., Kwiatkowski D.J. Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. The Lancet 2003, 361:1348-1349.
16. Furney S.J., Pedersen M., Gentien D., Dumont A.G., Rapinat A., Desjardins L., Turajlic S., Piperno-Neumann S., De la Grange P., Roman-Roman S., Stern M.-H., Marais R. SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov. 2013, 3:1122-1129.
17. Gragoudas E.S., Egan K.M., Seddon J.M., Glynn R.J., Walsh S.M., Finn S.M., Munzenrider J.E., Spar M.D. Survival of patients with metastases from uveal melanoma. Ophthalmology 1991, 98:383-390.
18. Griewank K.G., Yu X., Khalili J., Sozen M.M., Stempke-Hale K., Bernatchez C., Wardell S., Bastian B.C., Woodman S.E. Genetic and molecular characterization of uveal melanoma cell lines. Pigment Cell Melanoma Res. 2012, 25:182-187.
19. Harbour J.W. The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell Melanoma Res. 2012, 25:171-181.
20. Harbour J.W., Chen R. The DecisionDx-UM gene expression profile test provides risk stratification and individualized patient care in uveal melanoma. PLoS Curr. 2013, 5.
21. Harbour J.W., Onken M.D., Roberson E.D.O., Duan S., Cao L., Worley L.A., Council M.L., Matatall K.A., Helms C., Bowcock A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010, 330:1410-1413.
22. Harbour J.W., Roberson E.D.O., Anbunathan H., Onken M.D., Worley L.A., Bowcock A.M. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat. Genet. 2013, 45:133-135.
23. Ho A.L., Musi E., Ambrosini G., Nair J.S., Deraje Vasudeva S., De Stanchina E., Schwartz G.K. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 2012, 7:e40439.
24. Keith C.T., Borisy A.A., Stockwell B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 2005, 4:71-78.
25. Khalili J.S., Yu X., Wang J., Hayes B.C., Davies M.A., Lizee G., Esmaeli B., Woodman S.E. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin. Cancer Res. 2012, 18:4345-4355.
26. Kiliç E., Brüggenwirth H.T., Verbiest M.M.P.J., Zwarthoff E.C., Mooy N.M., Luyten G.P.M., De Klein A. The RAS-BRAF kinase pathway is not involved in uveal melanoma. Melanoma Res. 2004, 14:203-205.
27. Ksander B.R., Rubsamen P.E., Olsen K.R., Cousins S.W., Streilein J.W. Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. Invest. Ophthalmol. Vis. Sci. 1991, 32:3198-3208.
28. Laurent C., Gentien D., Piperno-Neumann S., Némati F., Nicolas A., Tesson B., Desjardins L., Mariani P., Rapinat A., Sastre-Garau X., Couturier J., Hupé P., De Koning L., Dubois T., Roman-Roman S., Stern M.-H., Barillot E., Harbour J.W., Saule S., Decaudin D. Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol. Oncol. 2013, 7:625-636.
29. Luyten G.P., Naus N.C., Mooy C.M., Hagemeijer A., Kan-Mitchell J., Van Drunen E., Vuzevski V., De Jong P.T., Luider T.M. Establishment and characterization of primary and metastatic uveal melanoma cell lines. Int. J. Cancer 1996, 66:380-387.
30. Mallone S., De Vries E., Guzzo M., Midena E., Verne J., Coebergh J.W., Marcos-Gragera R., Ardanaz E., Martinez R., Chirlaque M.D., Navarro C., Virgili G. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur. J. Cancer 2012, 48:1167-1175.
31. Martin M., Maßhöfer L., Temming P., Rahmann S., Metz C., Bornfeld N., Van de Nes J., Klein-Hitpass L., Hinnebusch A.G., Horsthemke B., Lohmann D.R., Zeschnigk M. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 2013, 45:933-936.
32. Marty B., Maire V., Gravier E., Rigaill G., Vincent-Salomon A., Kappler M., Lebigot I., Djelti F., Tourdès A., Gestraud P., Hupé P., Barillot E., Cruzalegui F., Tucker G.C., Stern M.-H., Thiery J.-P., Hickman J.A., Dubois T. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008, 10:R101.
33. Mitsiades N., Chew S.A., He B., Riechardt A.I., Karadedou T., Kotoula V., Poulaki V. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of b-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest. Ophthalmol. Vis. Sci. 2011, 52:7248-7255.
34. Némati F., Sastre-Garau X., Laurent C., Couturier J., Mariani P., Desjardins L., Piperno-Neumann S., Lantz O., Asselain B., Plancher C., Robert D., Péguillet I., Donnadieu M.-H., Dahmani A., Bessard M.-A., Gentien D., Reyes C., Saule S., Barillot E., Roman-Roman S., Decaudin D. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin. Cancer Res. 2010, 16:2352-2362.
35. Nyfeler B., Chen Y., Li X., Pinzon-Ortiz M., Wang Z., Reddy A., Pradhan E., Das R., Lehár J., Schlegel R., Finan P.M., Cao Z.A., Murphy L.O., Huang A. RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One 2012, 7:e48548.
36. Onken M.D., Worley L.A., Ehlers J.P., Harbour J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004, 64:7205-7209.
37. Pópulo H., Soares P., Faustino A., Rocha A.S., Silva P., Azevedo F., Lopes J.M. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res. 2011, 24:254-257.
38. Pópulo H., Soares P., Rocha A.S., Silva P., Lopes J.M. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 2010, 20:107-117.
39. Rimoldi D., Salvi S., Liénard D., Lejeune F.J., Speiser D., Zografos L., Cerottini J.-C. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003, 63:5712-5715.
40. Saraiva V.S., Caissie A.L., Segal L., Edelstein C., Burnier M.N. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res. 2005, 15:245-250.
41. Singh A.D., Topham A. Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology 2003, 110:962-965.
42. Singh A.D., Turell M.E., Topham A.K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011, 118:1881-1885.
43. Straussman R., Morikawa T., Shee K., Barzily-Rokni M., Qian Z.R., Du J., Davis A., Mongare M.M., Gould J., Frederick D.T., Cooper Z.A., Chapman P.B., Solit D.B., Ribas A., Lo R.S., Flaherty K.T., Ogino S., Wargo J.A., Golub T.R. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487:500-504.
44. Trolet J., Hupé P., Huon I., Lebigot I., Decraene C., Delattre O., Sastre-Garau X., Saule S., Thiéry J.-P., Plancher C., Asselain B., Desjardins L., Mariani P., Piperno-Neumann S., Barillot E., Couturier J. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest. Ophthalmol. Vis. Sci. 2009, 50:2572-2580.
45. Tuefferd M., De Bondt A., Van Den Wyngaert I., Talloen W., Verbeke T., Carvalho B., Clevert D.-A., Alifano M., Raghavan N., Amaratunga D., Göhlmann H., Broët P., Camilleri-Broët S. Genome-wide copy number alterations detection in fresh frozen and matched FFPE samples using SNP 6.0 arrays. Genes Chrom. Cancer 2008, 47:957-964.
46. Van Raamsdonk C.D., Bezrookove V., Green G., Bauer J., Gaugler L., O'Brien J.M., Simpson E.M., Barsh G.S., Bastian B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2008, 457:599-602.
47. Van Raamsdonk C.D., Griewank K.G., Crosby M.B., Garrido M.C., Vemula S., Wiesner T., Obenauf A.C., Wackernagel W., Green G., Bouvier N., Sozen M.M., Baimukanova G., Roy R., Heguy A., Dolgalev I., Khanin R., Busam K., Speicher M.R., O'Brien J., Bastian B.C. Mutations in GNA11 in uveal melanoma. N.Engl. J. Med. 2010, 363:2191-2199.
48. Weber A., Hengge U.R., Urbanik D., Markwart A., Mirmohammadsaegh A., Reichel M.B., Wittekind C., Wiedemann P., Tannapfel A. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab. Invest 2003, 83:1771-1776.
49. Weigelt B., Warne P.H., Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011, 30:3222-3233.